CIML NK cells (after 12–16 h of preactivation) were adoptively transferred to lymphodepleted patients with AML, and then, low doses of recombinant human IL-2 were administered to support memory-like NK cells expansion (27). This evidence concerns the gene IL2 and acute myeloid leukemia.